These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22273086)

  • 1. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.
    Kamat SA; Rajagopalan K; Stephenson JJ; Agarwal S
    Patient; 2009 Jun; 2(2):105-12. PubMed ID: 22273086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study.
    Stephenson JJ; Kern DM; Agarwal SS; Zeidman R; Rajagopalan K; Kamat SA; Foley J
    Health Qual Life Outcomes; 2012 Dec; 10():155. PubMed ID: 23270428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.
    Foley JF; Nair KV; Vollmer T; Stephenson JJ; Niecko T; Agarwal SS; Watson C
    Patient Prefer Adherence; 2017; 11():1035-1048. PubMed ID: 28670113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsing-remitting multiple sclerosis patients' experience with natalizumab: a phenomenological investigation.
    Miller CE; Karpinski M; Jezewski MA
    Int J MS Care; 2012; 14(1):39-44. PubMed ID: 24453731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TOUCH program and natalizumab: Fundamental flaw in patient protection.
    Avasarala J
    F1000Res; 2015; 4():1450. PubMed ID: 27134725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).
    Sabol RA; Noxon V; Sartor O; Berger JR; Qureshi Z; Raisch DW; Norris LB; Yarnold PR; Georgantopoulos P; Hrushesky WJ; Bobolts L; Ray P; Lebby A; Kane RC; Bennett CL
    Cancer Med; 2017 Jul; 6(7):1541-1551. PubMed ID: 28635055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
    Wiendl H; Spelman T; Butzkueven H; Kappos L; Trojano M; Su R; Campbell N; Ho PR; Licata S
    Mult Scler; 2021 Apr; 27(5):719-728. PubMed ID: 32579430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient perceived changes in sexual dysfunction after initiation of natalizumab for multiple sclerosis.
    Robertson D; Aungst A; Collier R; Vivar J; Moreo N; Casady L; Vu T
    Mult Scler J Exp Transl Clin; 2018; 4(2):2055217318781989. PubMed ID: 29977589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
    Hobart JC; Riazi A; Lamping DL; Fitzpatrick R; Thompson AJ
    Health Technol Assess; 2004 Mar; 8(9):iii, 1-48. PubMed ID: 14982653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2023 Mar; 37(3):275-289. PubMed ID: 36780107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
    Hersh CM; Kieseier B; de Moor C; Miller DM; Campagnolo D; Williams JR; Fitzgerald KC; Xiong K; McGinley MP; Hyland M; Rudick RA; Ziemssen T; Koulinska I
    Mult Scler J Exp Transl Clin; 2021; 7(2):20552173211004634. PubMed ID: 33948221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
    Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
    Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.